Dr. Hongwei Wang currently holds the position of Vice President, Oncology Global Development Lead, and Global Product Team Lead at BeiGene. In this capacity, she leads the cross-function global development teams and global product team of BeiGene’s lead IO asset, responsible for formulating the global product strategy of the asset and ensuring its successful development and commercialization through its brand life cycle. Additionally, she oversees the broad clinical development program and global regulatory submissions that span diverse indications and over 10 geographies. She also participates in global business development and oversees collaborative development programs with international business partners.
Hongwei was trained as a physician scientist and gained extensive cancer research experience over the past twenty-five years. For the recent fifteen years, she has primarily focused on oncology drug development in pharma-biotech industry. Before joining BeiGene, she served as Vice President, Head of Clinical Development at Karyopharm. There, she built and led the department of Clinical Development responsible for developing the strategy and executing a portfolio for early and late-stage oncology assets spanning multiple solid tumors and hematological malignancies, and played a significant role in the successful submission of multiple NDAs and regulatory approvals of XPOVIO. Prior to Karyopharm, Hongwei served in various clinical roles with increasing responsibilities at Novartis and Curis. Hongwei received her medical and doctoral degree from an eight-year medical education program and clinical training at Peking Union Medical College & Hospital. She pursued postgraduate training in translational research at MD Anderson Cancer Center, and then joined Brigham and Women's Hospital at Harvard Medical School where she completed a clinical research fellowship in Oncology.
Hongwei was trained as a physician scientist and gained extensive cancer research experience over the past twenty-five years. For the recent fifteen years, she has primarily focused on oncology drug development in pharma-biotech industry. Before joining BeiGene, she served as Vice President, Head of Clinical Development at Karyopharm. There, she built and led the department of Clinical Development responsible for developing the strategy and executing a portfolio for early and late-stage oncology assets spanning multiple solid tumors and hematological malignancies, and played a significant role in the successful submission of multiple NDAs and regulatory approvals of XPOVIO. Prior to Karyopharm, Hongwei served in various clinical roles with increasing responsibilities at Novartis and Curis. Hongwei received her medical and doctoral degree from an eight-year medical education program and clinical training at Peking Union Medical College & Hospital. She pursued postgraduate training in translational research at MD Anderson Cancer Center, and then joined Brigham and Women's Hospital at Harvard Medical School where she completed a clinical research fellowship in Oncology.
Speaking In
11:00 AM - 12:00 PM
Monday, June 5
